Skip to content
Screener

Other, net at other companies

Abbott logo
AbbottABT
-$20.5M
Artivion logo
ArtivionAORT
-$216K-23.4%
Boston Scientific logo
Boston ScientificBSX
$3M+130%
ITG
Integer HoldingsITGR
-$106K-251%
Haemonetics logo
HaemoneticsHAE
-$14K+61.1%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$1.7B+13.6%
Gross profit$1.3B+13.5%
Operating income$513.2M+24.8%
Net income$241.9M-27.4%
EPS (diluted)$0.42-25.0%

Balance sheet

See full
Cash & equivalents$2.4B-22.3%
Total debt$702.9M+0.5%
Total equity$10.3B+2.0%
Total assets$13.3B+2.3%

Cash flow

See full
Operating cash flow$43.8M-84.4%
CapEx$64.9M+15.9%
Free cash flow-$21.1M-109%

Valuation

See full
Market cap$51.48B+11.6%
Enterprise value$49.74B+11.0%
P/E51.2×+40.1×
P/S7.9×-0.2×

Profitability

See full
Gross margin77.8%-1.0pp
Operating margin22.3%-3.6pp
Net margin15.4%-57.5pp
FCF margin17.3%

Returns & leverage

See full
Return on equity10.7%-37.8pp
Debt / equity0.1×0.0×
Current ratio4.4×0.0×

Where this comes from

Reported directly by Edwards Lifesciences in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromPaymentsForOtherFinancingActivities.

The source filing: Edwards Lifesciences’s 10-Q, filed May 6, 2026.

Filed
May 6, 2026, 4:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001099800-26-000026
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Purchases of treasury stock(421.8)(258.6)
Equity forward contract related to accelerated share repurchase agreement (Note 11)(100.0)(50.0)
Proceeds from stock plans68.949.9
Other1.70.7
Net cash used in financing activities(451.2)(258.0)
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash8.2(17.7)
Net (decrease) increase in cash, cash equivalents, and restricted cash(492.0)90.0
Cash, cash equivalents, and restricted cash at beginning of period2,939.53,058.8

Item 1. Financial Statements (Unaudited)

FAQ

What is Edwards Lifesciences's other, net?
Edwards Lifesciences (EW) reported other, net of $1.7M in Q1 2026.
How has Edwards Lifesciences's other, net changed year-over-year?
Edwards Lifesciences's other, net increased by 142.9% year-over-year, from $700K to $1.7M.
What is the long-term trend for Edwards Lifesciences's other, net?
Over 2 years (2022 to 2025), Edwards Lifesciences's other, net has grown at a 0.0% compound annual growth rate (CAGR), from -$3.8M to -$3.8M.
What does other, net mean?
Includes miscellaneous cash flows related to financing activities that are not categorized as debt issuance, dividends, or share repurchases. This may include changes in non-controlling interests, debt issuance costs, or other unique financing-related transactions. It provides a comprehensive view of non-standard financing cash movements.

Ask your AI about Edwards Lifesciences's other, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude